Jacobio Pharmaceuticals
Beijing, China· Est.
Is this your company? Claim your profile to update info and connect with investors.
Claim profilePrivate Company
Funding information not available
Overview
An oncology-focused biotech pioneering small molecule inhibitors for undrugged targets like KRAS.
Oncology
Technology Platform
An integrated drug discovery and development platform focused on undrugged targets, particularly in the KRAS and kinase signaling pathways.
Opportunities
First-in-class or best-in-class potential for its pipeline candidates targeting validated but previously undruggable oncogenes.
Risk Factors
Clinical and commercial risk is high due to intense competition and the inherent difficulty of developing drugs for complex targets.
Competitive Landscape
A key competitor in the global race to develop KRAS inhibitors, facing off against large pharma and biotech firms.